TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Holdings Lifted by Barclays PLC

Barclays PLC lifted its position in TG Therapeutics, Inc. (NASDAQ:TGTX) by 83.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 347,057 shares of the biopharmaceutical company’s stock after acquiring an additional 158,323 shares during the quarter. Barclays PLC owned approximately 0.22% of TG Therapeutics worth $8,117,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. NBC Securities Inc. lifted its holdings in shares of TG Therapeutics by 58.9% in the third quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC acquired a new stake in TG Therapeutics during the 2nd quarter worth about $35,000. Blue Trust Inc. grew its stake in TG Therapeutics by 127.3% during the 3rd quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 849 shares in the last quarter. ORG Wealth Partners LLC acquired a new position in shares of TG Therapeutics in the 3rd quarter valued at about $53,000. Finally, Values First Advisors Inc. purchased a new stake in TG Therapeutics in the 3rd quarter worth approximately $58,000. Institutional investors and hedge funds own 58.58% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on TGTX. JPMorgan Chase & Co. raised their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. TD Cowen initiated coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price for the company. HC Wainwright increased their price target on TG Therapeutics from $49.00 to $55.00 and gave the company a “buy” rating in a report on Tuesday, November 5th. Finally, The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $40.67.

Insider Buying and Selling

In other TG Therapeutics news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the sale, the director now owns 100,195 shares in the company, valued at $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 10.50% of the stock is owned by company insiders.

TG Therapeutics Stock Down 2.4 %

Shares of TGTX stock opened at $33.57 on Wednesday. The stock has a 50 day moving average of $29.06 and a 200-day moving average of $23.69. The firm has a market cap of $5.23 billion, a PE ratio of -335.70 and a beta of 2.25. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. TG Therapeutics, Inc. has a 12 month low of $12.84 and a 12 month high of $36.84.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $83.90 million during the quarter, compared to the consensus estimate of $81.68 million. During the same period last year, the company earned $0.73 earnings per share. TG Therapeutics’s revenue for the quarter was down 49.4% on a year-over-year basis. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.